LPX-TI641Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

Sponsor:

LAPIX Therapeutics Inc.

Code:

NCT06982352

Conditions

Atopic Dermatitis (AD)

Psoriasis (PsO)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

LPX-TI641

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by LAPIX Therapeutics Inc. on 2025-12-19.